Data investigation

The Head-to-Head, and What It Settles

751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·3 citations

This is the trial everyone wanted. Seven hundred and fifty-one adults with obesity and without diabetes, randomized to tirzepatide or semaglutide, each at the highest dose they could tolerate, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%.[1] On weight, the question is settled. On several other questions this register has covered, the answer runs the other way.

Why this comparison is fair

Most claimed comparisons between these two drugs are not comparisons at all. They set one trial’s headline beside another’s, which measures the trials as much as the drugs. This trial is different: it randomized one group of participants to the two drugs, over the same period, under the same protocol.

It also avoids the criticism that sank an earlier comparison. Both arms ran to their own maximum tolerated dose: tirzepatide at 10 or 15 mg, semaglutide at 1.7 or 2.4 mg. Semaglutide 2.4 mg is its full weight-management dose, so nobody was held back. That answers the objection we raised about a different analysis, which set tirzepatide’s full range against semaglutide at the 1 mg diabetes dose (see a composite is only its components). Because Mounjaro is the same tirzepatide under a diabetes label, this is also the trial behind most Wegovy and Mounjaro comparisons.

SURMOUNT-5 at 72 weeks.[1]
OutcomeTirzepatideSemaglutide
Weight change−20.2% (95% CI −21.4 to −19.1)−13.7% (−14.9 to −12.6)
Waist circumference−18.4 cm−13.0 cm
Reaching 10%, 15%, 20% and 25% lossMore likely at every threshold—

Both differences reached P<0.001. Gastrointestinal effects dominated in both arms, mostly mild to moderate, mostly during dose escalation.

The design flaw that is worth naming

The trial was open-label. Every participant knew which drug they had drawn. When the primary endpoint is body weight, and one of the two drugs carries a widespread public reputation as the stronger one, that is not a trivial detail. Expectation influences adherence, effort, and everything people do around a medication.

This is unavoidable to a degree, since the two drugs titrate differently and blinding would require elaborate dummy injections. It is still the reason a 6.5 percentage point gap should be read as approximately right rather than precisely measured.

The trial was funded by Eli Lilly, which makes tirzepatide. That is normal for a phase 3b head-to-head, and it still belongs on the page when the sponsor’s drug won.

What 'better' does not follow from

Tirzepatide removes more weight. Whether it is the better drug depends on which outcome you are buying, and on several of them our other articles have found a different answer, including one from this same trial.

The same two drugs, on other endpoints.
QuestionWhat the evidence says
Quality of life, in this trialMental component improved in neither arm over 72 weeks — details
Preventing deathSubcutaneous semaglutide is the only drug with a mortality signal across 262 trials — details
Heart failure outcomesNo meaningful difference between them (HR 0.86, 0.70–1.06) — details
Lean massTirzepatide loses the most fat (25.7%) and the most lean mass (8.3%) — details
Does the benefit track the weight?In SELECT, cardiovascular protection was largely independent of weight lost — details
Value for moneyA lifetime cost model built on this trial projects tirzepatide saving $41,688 per patient; it was computed, not measured
The drug that removes more weight is not the drug with the outcome evidence.

That is not a reason to prefer semaglutide either. It means “which is better” hides a second question, better at what, and the answer changes depending on how you fill it in.

How to actually use this

  • If the goal is the largest weight reduction, this trial answers it directly and in tirzepatide’s favor.
  • If the goal is cardiovascular risk with established disease, the evidence depends on who you are. Semaglutide has placebo-controlled outcome trials, including SELECT in people with overweight or obesity and no diabetes. In type 2 diabetes with heart disease, tirzepatide now has SURPASS-CVOT, where it was noninferior to dulaglutide but did not reach superiority (hazard ratio 0.92; 95.3% CI, 0.83 to 1.01).[2] In obesity without diabetes, tirzepatide has no outcomes result yet; SURMOUNT-MMO is still running.[3]
  • Tolerability is individual and not settled by a group mean. The drug you can stay on beats the drug you stop, and slower titration has randomized evidence behind it (see five clicks).
  • Cost, coverage and supply decide this for most people more often than either trial does.

For each drug’s own record on its own terms, see the tirzepatide timeline and the semaglutide timeline.

Frequently Asked Questions

Yes, on the direct evidence. In SURMOUNT-5, 751 adults with obesity and without diabetes were randomized to each drug at its maximum tolerated dose for 72 weeks, and tirzepatide produced 20.2% weight loss against 13.7%.
Yes. Both arms ran to their own maximum tolerated dose: tirzepatide at 10 or 15 mg and semaglutide at 1.7 or 2.4 mg, which is semaglutide's full weight-management dose. This is not the dose mismatch that limits some other comparisons.
It was open-label, so everyone knew which drug they were taking. When the endpoint is weight and one drug has a public reputation as the stronger one, expectation affects behavior. The gap should be read as approximately right rather than precisely measured.
For weight, yes. On other endpoints the answer differs: neither arm improved on the mental component of quality of life in this same trial, semaglutide is the only agent with a mortality signal across a 262-trial synthesis, and the two showed no meaningful difference on hard heart failure outcomes.
It depends on what the treatment is for, on what can be tolerated, and in practice on cost and coverage. The drug someone can stay on outperforms the drug they stop.

References

  1. 1.Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine. 2025. PMID: 40353578.
  2. 2.Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine. 2025. PMID: 41406444.
  3. 3.Eli Lilly and Company A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO), NCT05556512 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05556512

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →